ロード中...
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from init...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2858493/ https://ncbi.nlm.nih.gov/pubmed/20197552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-233304 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|